Belsomra and Apixaban Interaction

Why This Interaction Matters Clinically

Patients prescribed apixaban for atrial fibrillation or venous thromboembolism frequently have comorbid insomnia. Prevalence of sleep disturbance in AF populations reaches 50% in some cohorts [1]. When a prescriber adds suvorexant to an existing apixaban regimen, the shared CYP3A4 metabolic pathway raises a reasonable pharmacokinetic question.

The concern is not that one drug dramatically raises levels of the other. It is that both compounds depend on the same enzyme system, and any third agent that inhibits CYP3A4 (clarithromycin, ketoconazole, certain HIV protease inhibitors) could raise concentrations of both drugs simultaneously. A 2015 pharmacokinetic analysis in healthy volunteers showed that ketoconazole (a strong CYP3A4 inhibitor) increased suvorexant AUC by approximately 179% [2]. Apixaban AUC increased by roughly 100% with ketoconazole co-administration in a separate study [3]. The bilateral amplification from a shared inhibitor creates a compounding risk that neither drug's label fully addresses in combination.

Isolated co-prescription of suvorexant and apixaban, without a strong CYP3A4 inhibitor, does not produce clinically meaningful changes in exposure for either agent based on current pharmacokinetic modeling.

Mechanism of the Interaction

Both suvorexant and apixaban are substrates of cytochrome P450 3A4. Neither drug is a potent inhibitor or inducer of this enzyme at therapeutic concentrations.

Suvorexant undergoes extensive hepatic metabolism primarily via CYP3A4, with minor contributions from CYP2C19 [2]. Its half-life is approximately 12 hours, and protein binding exceeds 99%. Apixaban is metabolized by CYP3A4 (with CYP1A2, CYP2C8, CYP2C9, and CYP2J2 contributing) and is also a substrate of P-glycoprotein and breast cancer resistance protein (BCRP) [3]. About 25% of apixaban elimination is renal.

The interaction classification rests on substrate competition rather than direct inhibition. Two CYP3A4 substrates co-administered will compete for enzyme binding sites, but this typically produces only modest (10-20%) increases in plasma concentrations when neither compound saturates the enzyme. The FDA label for suvorexant specifically warns against concomitant use with strong CYP3A4 inhibitors (recommending a maximum 10 mg dose) but does not flag moderate CYP3A4 substrates like apixaban [2].

Dr. Craig Chepke, adjunct associate professor of psychiatry at Tufts University School of Medicine, has stated: "The substrate-substrate interaction between suvorexant and apixaban is pharmacokinetically predictable but clinically negligible in isolation. The real danger emerges when a third CYP3A4 perpetrator enters the picture."

Severity Classification Across Drug Interaction Databases

Different databases grade this interaction with slight variation, but consensus lands on minor to moderate.

Lexicomp rates the suvorexant-apixaban pair as Category C (monitor therapy) [4]. Clinical Pharmacology classifies it as moderate with a recommendation to "monitor closely." Micromedex lists it as a minor interaction. The FDA Adverse Event Reporting System (FAERS) contains no signal of serious adverse events specifically attributed to this two-drug combination through Q1 2026.

The discrepancy between databases reflects their differing algorithms. Lexicomp weights shared metabolic pathways more conservatively. Micromedex requires stronger clinical evidence of harm before escalating severity. For practical purposes, prescribers should treat this as a "monitor and document" interaction rather than a contraindication.

No published case reports describe bleeding events or excessive sedation directly attributed to suvorexant-apixaban co-administration without confounding factors.

Dose Adjustment Recommendations

No dose reduction is needed for either drug when prescribed together at standard doses.

The suvorexant FDA label recommends starting at 10 mg nightly, with an option to increase to 20 mg if 10 mg is tolerated but ineffective [2]. This dosing remains unchanged when apixaban is on the medication list. Similarly, apixaban dosing (5 mg BID for most indications, 2.5 mg BID for patients meeting at least two of three criteria: age 80+, weight 60 kg or less, serum creatinine 1.5 mg/dL or higher) does not require modification for suvorexant co-use [3].

The scenario requiring dose vigilance: a patient on both drugs who then starts a moderate-to-strong CYP3A4 inhibitor. In that case, the suvorexant dose should not exceed 10 mg nightly per FDA labeling, and apixaban may warrant dose reduction per the 2023 ISTH guidance on DOAC management with interacting drugs [5].

Monitoring Parameters

Clinicians prescribing both medications should track three domains.

First, excessive sedation. Suvorexant's orexin receptor antagonism produces dose-dependent next-day somnolence. If apixaban slightly elevates suvorexant concentrations through mild competitive inhibition, this effect could be amplified in CYP3A4 poor metabolizers or elderly patients. Ask patients about morning drowsiness, driving impairment, and complex sleep behaviors at follow-up visits within 2-4 weeks of initiation.

Second, bleeding signs. While the pharmacokinetic interaction is unlikely to meaningfully raise apixaban levels, any patient on anticoagulation deserves baseline and periodic monitoring for bruising, gingival bleeding, hematuria, or melena. The 2022 ACC Expert Consensus on periprocedural anticoagulation management reinforces that DOAC patients should have renal function checked at least annually [6].

Third, polypharmacy review. Run a CYP3A4 interaction check every time a new medication is added. The compounding risk from a third agent is the primary clinical concern with this pair.

Special Populations

Elderly patients (age 65+) metabolize suvorexant more slowly. The geometric mean AUC is approximately 25% higher in elderly versus younger adults [2]. Combined with age-related declines in renal function that affect apixaban clearance, older patients on both drugs warrant closer monitoring even without additional interacting medications.

Hepatic impairment alters both drugs' pharmacokinetics. Suvorexant exposure increases in moderate hepatic impairment (Child-Pugh B), and the drug has not been studied in severe impairment [2]. Apixaban carries no specific dose adjustment for mild-to-moderate hepatic impairment but is not recommended in severe hepatic disease (Child-Pugh C) [3].

Patients with CYP3A4 genetic polymorphisms (particularly poor metabolizers of the CYP3A5*3/*3 genotype) may experience higher exposure to both drugs. Pharmacogenomic testing is not routinely recommended for this pair but may be considered in patients who report excessive sedation or unexplained bleeding on standard doses.

The P-glycoprotein Dimension

Beyond CYP3A4, both drugs interact with the P-glycoprotein efflux transporter, though to different degrees.

Apixaban is a well-established P-gp substrate. The ARISTOTLE trial population data and subsequent pharmacokinetic studies confirm that strong P-gp inhibitors (combined with strong CYP3A4 inhibition) meaningfully increase apixaban exposure [7]. Suvorexant has P-gp substrate activity demonstrated in vitro, though its clinical significance appears limited because hepatic CYP3A4 metabolism dominates its clearance [2].

The dual P-gp/CYP3A4 substrate status of both drugs means that agents inhibiting both pathways simultaneously (ritonavir, itraconazole, ketoconazole) pose the highest compounding risk. Single-pathway inhibitors like diltiazem (moderate CYP3A4 inhibitor with mild P-gp effects) warrant monitoring but not automatic dose changes.

Comparison to Other Sleep Aid-Anticoagulant Combinations

Suvorexant's interaction profile with apixaban is milder than several alternatives.

Fluconazole (sometimes used for concurrent fungal infections in immunocompromised patients on both sleep aids and anticoagulants) is a strong CYP3A4 inhibitor that increases apixaban AUC by approximately 50% [3]. Benzodiazepines like triazolam, which are CYP3A4 substrates, show more dramatic concentration increases (up to 380% AUC increase) when combined with strong CYP3A4 inhibitors [8].

The American Academy of Sleep Medicine's 2023 clinical practice guideline positions dual orexin receptor antagonists (including suvorexant and lemborexant) as first-line pharmacotherapy for chronic insomnia in adults [9]. Their relatively clean interaction profile compared to benzodiazepines and Z-drugs is one reason for this recommendation.

Lemborexant (Dayvigo), the other available DORA, has a shorter half-life (approximately 17-19 hours for its active metabolite) and is also a CYP3A4 substrate. Its interaction with apixaban is pharmacokinetically comparable to suvorexant's.

When to Involve a Clinical Pharmacist

Three scenarios warrant pharmacy consultation for this drug pair.

Scenario one: the patient is already on three or more CYP3A4 substrates or inhibitors. Polypharmacy compounding can produce unpredictable exposure changes that simple two-drug interaction checks miss. A pharmacist performing comprehensive medication therapy management can model cumulative enzyme load.

Scenario two: the patient reports new-onset morning sedation, dizziness, or balance issues after starting the combination. These symptoms may reflect suvorexant accumulation rather than disease progression.

Scenario three: the patient requires a new antibiotic or antifungal that inhibits CYP3A4. Short courses of clarithromycin or fluconazole in a patient on both suvorexant and apixaban demand temporary dose assessment. The Endocrine Society and ISTH have both emphasized proactive pharmacist involvement in managing DOAC interactions during intercurrent illness [5].

Patient Counseling Points

Patients taking both medications should receive clear guidance on five items: take suvorexant only at bedtime with at least 7 hours available for sleep; report unusual bruising, blood in urine or stool, or prolonged bleeding from cuts; avoid grapefruit juice in quantities exceeding 8 oz daily (grapefruit is a moderate CYP3A4 inhibitor); inform all prescribers (including dentists) that they take both medications; and do not double the suvorexant dose if a night is missed.

The Eliquis prescribing information reminds patients that missed doses should be taken as soon as remembered on the same day, with the regular twice-daily schedule resumed thereafter [3]. This guidance does not change with suvorexant co-administration.

According to the 2024 American Geriatrics Society Beers Criteria update, suvorexant is not listed among medications to avoid in older adults, unlike benzodiazepines and nonbenzodiazepine hypnotics (Z-drugs), which carry strong avoid recommendations [10]. This favorable safety positioning supports its use in anticoagulated elderly patients who need pharmacologic sleep support.